Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer

BACKGROUND: Regorafenib and its metabolites may inhibit the activities of several CYP or UDP-glucuronosyltransferase isoforms, including that of CYP2C9. Therefore, pharmacological agents that are CYP2C9 substrates may show elevated circulating levels and enhanced drug efficacy when concurrently used...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitade, Hironori, Hiromasa-Yamasaki, Azusa, Hokkoku, Kengo, Mori, Mitsue, Watanabe, Michio, Nakai, Masuo, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937497/
https://www.ncbi.nlm.nih.gov/pubmed/27398225
http://dx.doi.org/10.1186/s40780-016-0050-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937497/
https://www.ncbi.nlm.nih.gov/pubmed/27398225
http://dx.doi.org/10.1186/s40780-016-0050-y

Ejemplares similares